Complication and management of polymethylmethacrylate (PMMA) injections to the midface
| Autor: | André Borba, Patricia Akaishi, Roberto Murillo Limongi, Ana Rosa Pimentel, Antonio Augusto Velasco e Cruz, Filipe José Pereira, Jeremiah P. Tao |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Injectable filler medicine.medical_specialty Erythema medicine.drug_class Injections Subcutaneous Cosmetic Techniques Injections Intralesional 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones Edema Dermal Fillers medicine Humans Polymethyl Methacrylate Rejuvenation OFTALMOPATIAS Retrospective Studies Inflammation business.industry Retrospective cohort study General Medicine Middle Aged Debulking Surgery Skin Aging medicine.anatomical_structure Treatment Outcome Face 030221 ophthalmology & optometry Eyelid Diseases Corticosteroid Histopathology Female Eyelid medicine.symptom business Pigmentation Disorders |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| Popis: | Background Polymethylmethacrylate (PMMA) has been used as an injectable filler to treat hollows and reduce rhytids. PMMA injections have been associated with several side effects, however, the literature is scarce on periorbital complications and their treatments. Objectives The purpose of this study is to report a series of complications after periorbital PMMA injections to the midface and to describe their management. Methods Retrospective chart review, including photography and histopathology when available. Results The authors identified 11 cases of complications of PMMA injections to the midface. Patient ages ranged from 36 to 62 years (mean, 47 years; median, 44 years). Two (18%) were males and 9 (82%) were females. Adverse effects began between 2 to 24 months after injection (mean, 7.2 months; median, 6 months). All patients had edema, erythema, and contour irregularity. Seven (64%) patients had nodules, 4 (36%) had yellow, xanthomatous skin changes, and 2 (18%) had eyelid malposition. Histopathology demonstrated a giant cell inflammation in 5 of 6 cases. Corticosteroid injection was tried in 6 cases but was associated with minimal clinical improvement. Surgical debulking of the implanted material was performed in 9 (82%) cases and was effective in improving edema, erythema, and nodularity. Conclusions PMMA injection to the midface may be associated with chronic inflammation, fibrotic nodules, yellowing of the skin, and eyelid malposition. Intralesional corticosteroid injections yielded minimal or no improvement; surgical debulking achieved favorable results. Level of Evidence 4 ![Graphic][1] Therapeutic [1]: /embed/inline-graphic-1.gif |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|